

Supplemental Material Table of Contents

Supplemental Figure 1: PCA1-4 in Cases and Controls in the UK biobank. Available at UK Biobank data field 22009.

Supplemental Figure 2: Q-Q Plot for Centrally HRC-imputed Hematuria GWAS. The Q-Q plot is a graphical representation of the deviation of the observed P values from the null hypothesis stratified by quartiles of minor allele frequencies. Figure generated using summary statistics from <https://pheweb.org/UKB-SAIGE/pheno/593>.

Supplemental Table 1. Descriptive characteristics of UK Biobank white British subset used in the hematuria analyses.

Supplemental Table 2. Association of 3 independent *COL4A4-COL4A3* variants with other kidney-disease relevant or Alport syndrome traits using TOPMed imputed UK Biobank dataset. Source is pheweb.org.

Supplemental Table 3. GWAS via SAIGE using *HLA* haplotypes provided by UK Biobank on white British for ICD-based case-control hematuria. After conditioning on *HLA-B*0801*, which was the strongest association (row 59, red), no other associations were statistically significant (highlighted in blue) including IgA nephropathy haplotypes reported by Kiryluk K et al Nature Genetics 2014 (PMID:25305753) shown in rows 275 (*DQB1*0201*, yellow), 277 (*DQB1*0301*, yellow), 294 (*DQA1*0102*, yellow) and 295 (*DQA1*0103*, yellow).

Supplemental Table 4. Novel hematuria loci in UK Biobank are replicated in deCODE dataset, though association with variant, nearest gene *PDPN* is nominal. Results for phenotype defined as $\geq 2+$ hematuria or $\geq 1+$ hematuria are both shown for each of the novel loci.

Supplemental Table 5. Cell and tissue specific expression of novel loci in hematuria GWAS. Associated phenotypes from pheweb.org also shown. LH=loop of Henle, DCT=distal convoluted tubule, CNT=connecting tubule, PC=principal cell, IC-A=intercalated cell A, EC=endothelial cell

Supplemental Table 6. Estimated pairwise linkage disequilibrium between UK Biobank imputed haplotypes *HLA-B*0801*, *HLA-DQB1*0201* and *HLA-DQB1*0301* for the white British hematuria cases and controls.

Supplemental Table 7. *HLA* haplotype frequencies.


Supplemental Table 8. Estimated haplotype frequencies for *HLA-B*0801* and *HLA-DQB1*0201* in white British in UK Biobank.

Supplemental Table 9. Estimated haplotype frequencies for *HLA-B*0801* and *HLA-DQB1*0301* in white British in UK Biobank.


Supplemental Table 10. Estimated haplotype frequencies for *HLA-DQB1*0201* and *HLA-DQB1*0301* in white British in UK Biobank.

Supplemental Figure 1: PCA1-4 in Cases and Controls in the UK biobank. Available at UK Biobank data field 22009.


Controls




Cases




Controls



Cases



Supplemental Figure 2: Q-Q Plot for Centrally HRC-imputed Hematuria GWAS. The Q-Q plot is a graphical representation of the deviation of the observed P values from the null hypothesis stratified by quartiles of minor allele frequencies. Figure generated using summary statistics from <https://pheweb.org/UKB-SAIGE/pheno/593>.



MAF [.05,.5] (5432396)	○
MAF [.01,.05) (2310010)	▲
MAF [.005,.01) (1074851)	□
MAF [.0001,.005) (13086692)	●
MAF (0,.0001) (6328746)	▼

Supplemental Table 1: Descriptive characteristics of UK biobank white British subset used in the hematuria analyses.

	Cases	Controls	Cases with non-missing data	Controls with non-missing data	T-test p-value
Total (female+male)	16,866 (7,074+9,292)	391,420 (213,407+178,013)	--	--	< 2.2E-16 (chi-square)
Age at baseline in years, mean±SD	59.7±7.2	56.8±8.0	16,866	391,420	< 2.2E-16
Number of individuals on the 2 arrays	UK BiLEVE: 2043 UK Biobank Axiom: 14,823	UK BiLEVE: 42,542 UK Biobank Axiom: 348,878	16,866	391,420	3.90E-07 (chi-square)
PC1, mean±SD	-12.36±1.61	-12.36±1.61	16,866	16,866	0.75
PC2, mean±SD	3.78±1.50	3.78±1.50	16,866	16,866	0.99
Pulse rate, automated reading at baseline in bpm, mean±SD	70.0±12.1	69.5±11.7	15,731	365,689	7.1E-07
Systolic blood pressure, automated reading at baseline in mmHg, mean±SD	142.7±19.8	140.1±19.6	15,731	365,682	< 2.2E-16
Diastolic blood pressure, automated reading at baseline in mmHg, mean±SD	82.7±10.8	82.2±10.6	15,731	365,682	1.115E-08
Taking blood pressure medication at baseline	2336 (1010 females + 1326 males)	38,892 (21,438 females + 17,454 males)	16,842 (7061 females + 9781 males)	390,756 (213,030 females + 177,726 males)	< 2.2E-16 (chi-square)
Standing height at baseline in cm, mean±SD	169.8±9.26	168.7±9.25	16,798	390,632	< 2.2E-16
Weight at baseline in Kg, mean±SD	81.24±16.7	78.15±15.8	16,781	390,371	< 2.2E-16
BMI at baseline, mean±SD	28.08±4.93	27.38±9.26	16,773	390,233	< 2.2E-16
Urinary Albumin-Creatinine Ratio in mg/mmol*, Median (1 st -3 rd percentile)	1.19 (0.73-2.13)	1.10 (0.69-1.85)	16,399	380,240	< 2.2E-16 (Mann-Whitney U test)
eGFR in mL/min/1.72m ² **, mean±SD	87.39±14.6	90.67±13.2	16,123	372,966	< 2.2E-16

eGFR computed as 100/serum cystatin C (mg/L) at baseline, mean±SD	107.53±18.5	113.3± 17.6	16,122	373,134	< 2.2E-16
Hearing aid user (yes; no)	809; 9,617	11,876; 223,977	10,426	235,853	< 2.2E-16 (chi-square)
Hearing difficulty/problems via touchscreen (yes; no)	5,205; 11,014	97,706; 278,260	16,219	375,966	< 2.2E-16 (chi-square)

Supplemental Table 2: Association of 3 independent *COL4A4-COL4A3* variants with other renally relevant or Alport syndrome traits using TOPMed imputed UK Biobank dataset. Source is pheweb.org. Effect size is to alternate allele.

Gene, SNP	Phenotype	P-value	Beta (SE)	Number of samples (cases/controls)	
<i>COL4A4</i> p.Ser969X rs35138315	Hematuria	8.8E-49	4.5 (0.31)	16235/378356	
	Essential hypertension	6.8E-7	0.61 (0.12)	77465/328796	
	Hypertension	8.0E-7	0.61 (0.12)	77714/328796	
	Other symptoms/disorders of the urinary system	8.9E-5	3.6 (0.92)	1387/396050	
	Retinal detachment with retinal defect	9.6E-5	3.6 (0.92)	1387/396050	
	Nephritis and nephropathy with pathological lesion	1.3E-4	11 (2.9)	252/395835	
	Chronic glomerulonephritis, NOS	1.4E-4	4.6 (1.2)	877/395835	
	Nephritis; nephrosis; renal sclerosis	2.0E-4	3.2 (0.85)	1531/395835	
	Glomerulonephritis	4.3E-4	3.7 (1.1)	1052/395835	
	Proteinuria	5.6E-4	7.4 (2.1)	337/406470	
	Myopia	7.5E-4	3.3 (0.97)	1249/404788	
	Chronic renal failure	8.4E-4	2.0 (0.60)	2649/395832	
	Retinal detachments and defects	9.4E-4	1.8 (0.55)	3244/396051	
	<i>COL4A4</i> intron 25 variant rs58261427	Hematuria	1.2E-9	0.086 (0.014)	16235/378356
		Hearing loss	7.6E-3	0.072 (0.027)	4192/402829
	Conductive hearing loss	9.3E-3	0.21 (0.082)	449/402828	

	Chronic glomerulonephritis, NOS	9.9E-3	-0.15 (0.059)	877/395835
	Glomerulonephritis	1.1E-2	-0.14 (0.054)	1053/395835
	Chronic renal failure	1.1E-2	-0.087 (0.034)	2649/395832
	Sensorineural hearing loss	1.5E-2	0.20 (0.081)	455/402829
<hr/>				
<i>COL4A3</i> p.Gly695Arg rs200287952	Hematuria	1.7E-8	3.9 (0.68)	16235/378356
	Type 1 diabetes with ophthalmic manifestations	1.2 E-3	18 (5.7)	473/387081
	Type 2 diabetes with ophthalmic manifestations	1.6E-3	10 (3.2)	986/387082
	Diabetic retinopathy	3.6E-3	7.5 (2.6)	1330/395155
	Other hypertensive complications	8.0E-3	28 (11)	144/328788
	Benign neoplasm of kidney and other urinary organs	9.2E-3	24 (9.3)	173/369609
	Small kidney	1.1E-2	23 (9.0)	179/395834
	Preeclampsia and eclampsia	1.2E-2	19 (76)	306 (218980)

Supplemental Table 5. Cell and tissue specific expression of novel loci in hematuria GWAS. Associated phenotypes from pheweb also shown. LH=loop of Henle, DCT=distal convoluted tubule, CNT=connecting tubule, PC=principal cell, IC-A=intercalated cell A, EC=endothelial cell

Nearest gene and SNP	snRNAseq in healthy human adult kidney (4,524 nuclei; humphreyslab.com)	GTex V8 Median TPM in kidney	PheWas https://pheweb.org/UKB-TOPMed/
<i>PDPN</i> , rs2885134	podocyte	2.193 (cortex), 1.748 (medulla)	Hematuria, p=4.9E-9, effect size 0.21 (0.035)
<i>SORL1</i> , rs618048	LH, DCT, CNT, PC, IC-A	8.9 (cortex), 14.46 (medulla)	-
<i>PLLPL</i> , rs948705	PT (S3), IC-A, IC-B	9.247 (cortex), 9.425 (medulla)	-
<i>CCDC97</i> , <i>TGFBI</i> , rs56254331	EC, IC-A (<i>TGFBI</i>)	<i>CCDC97</i> : 9.45 (cortex), 11.66 (medulla); <i>TGFBI</i> : 32.47 (cortex), 46.64 (medulla)	Hematuria, p=8.1E-16, effect size -0.12 (0.15) other disorders of the kidney and ureters, p=1.6E-3, effect size=-0.10 (0.33)

Supplemental Table 6. Estimated pairwise linkage disequilibrium between UK Biobank imputed haplotypes *HLA-B**0801, *HLA-DQB1* *0201 and *HLA-DQB1* *0301 for the white British hematuria cases and controls.

Haplotype pair	r ²	D'
<i>HLA-B</i> *0801 & <i>HLA-DQB1</i> *0201	0.47	0.69
<i>HLA-B</i> *0801 & <i>HLA-DQB1</i> *0301	0.01	0.28
<i>HLA-DQB1</i> *0201 & <i>HLA-DQB1</i> *0301	0.02	0.34

Supplemental Table 7. *HLA* haplotype frequencies.

Haplotype	Frequency
<i>HLA-B</i> *0801 & <i>HLA-DQB1</i> *0201	18%
<i>HLA-B</i> *0801 & <i>HLA-DQB1</i> *0301	5.2%
<i>HLA-DQB1</i> *0201 & <i>HLA-DQB1</i> *0301	5.0%

Supplemental Table 8. Estimated haplotype frequencies for *HLA-B**0801 and *HLA-DQB1**0201 in white British in UK Biobank.

<i>HLA-B</i> *0801	<i>HLA-DQB1</i> *0201	Observed Frequency	Expected Frequency under linkage equilibrium
<i>HLA-B</i> *0801	<i>HLA-DQB1</i> *0201	0.188	0.061
not	<i>HLA-DQB1</i> *0201	0.063	0.190
<i>HLA-B</i> *0801	not	0.056	0.183
not	not	0.693	0.566

Supplemental Table 9. Estimated haplotype frequencies for *HLA-B**0801 and *HLA-DQB1**0301 in white British in UK Biobank.

<i>HLA-B</i> *0801	<i>HLA-DQB1</i> *0301	Observed Frequency	Expected Frequency under linkage equilibrium
<i>HLA-B</i> *0801	<i>HLA-DQB1</i> *0301	0.052	0.072
not	<i>HLA-DQB1</i> *0301	0.231	0.211
<i>HLA-B</i> *0801	not	0.203	0.183
not	not	0.513	0.533

Supplemental Table 10. Estimated haplotype frequencies for *HLA-DQB1*0201* and *HLA-DQB1*0301* in white British in UK Biobank.

<i>HLA-DQB1*0201</i>	<i>HLA-DQB1*0301</i>	Observed Frequency	Expected Frequency under linkage equilibrium
<i>HLA-DQB1*0201</i>	<i>HLA-DQB1*0301</i>	0.050	0.075
not	<i>HLA-DQB1*0301</i>	0.236	0.210
<i>HLA-DQB1*0201</i>	not	0.214	0.188
not	not	0.501	0.526